UY29627A1 - Derivados de prostaglandina - Google Patents

Derivados de prostaglandina

Info

Publication number
UY29627A1
UY29627A1 UY29627A UY29627A UY29627A1 UY 29627 A1 UY29627 A1 UY 29627A1 UY 29627 A UY29627 A UY 29627A UY 29627 A UY29627 A UY 29627A UY 29627 A1 UY29627 A1 UY 29627A1
Authority
UY
Uruguay
Prior art keywords
prostaglandina
derivatives
nitroderivatives
glaucoma
treatment
Prior art date
Application number
UY29627A
Other languages
English (en)
Inventor
Valerio Chiroli
Francesca Benedini
Wesley Kuan Mung Chong
Achim Krauss
Michael Ross Niesman
Ennio Ongini
Original Assignee
Pfizer
Nicox Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Nicox Sa filed Critical Pfizer
Publication of UY29627A1 publication Critical patent/UY29627A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen nitroderivados de amidas de prostaglandina que tienen mejor actividad farmacológica y mayor tolerabilidad. Se pueden emplear para el tratamiento del glaucoma y la hipertensión ocular.
UY29627A 2005-06-29 2006-06-27 Derivados de prostaglandina UY29627A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69638305P 2005-06-29 2005-06-29

Publications (1)

Publication Number Publication Date
UY29627A1 true UY29627A1 (es) 2007-01-31

Family

ID=37309319

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29627A UY29627A1 (es) 2005-06-29 2006-06-27 Derivados de prostaglandina

Country Status (11)

Country Link
US (1) US7718656B2 (es)
EP (1) EP1899295A2 (es)
JP (1) JP2009501150A (es)
AR (1) AR057414A1 (es)
CA (1) CA2613748A1 (es)
GT (1) GT200600277A (es)
NL (1) NL1032046C2 (es)
PE (1) PE20070120A1 (es)
TW (1) TW200730179A (es)
UY (1) UY29627A1 (es)
WO (1) WO2007000641A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2677387C (en) * 2007-02-05 2016-06-21 Nicox S.A. Nitric oxide donor compounds
US7960379B2 (en) 2008-03-14 2011-06-14 Allergan, Inc. Therapeutic compounds
AR076731A1 (es) * 2008-05-09 2011-07-06 Pfizer Prostamidas donadoras de oxido nitrico, uso de los mismos y composiciones farmaceuticas
WO2013126156A1 (en) * 2012-02-22 2013-08-29 Bausch & Lomb Incorporated Nitric oxide donating selective glucocorticoid receptor agonist compounds and ophthalmic compositions
EP2826491A1 (en) * 2013-07-15 2015-01-21 Nicox Science Ireland Ophthalmic compositions containing a nitric oxide donor
US9604949B2 (en) * 2014-10-15 2017-03-28 Novartis Ag Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension
WO2016155906A1 (en) * 2015-03-31 2016-10-06 Nicox S.A. Nitric oxide donating derivatives of fluprostenol
WO2016156104A1 (en) 2015-03-31 2016-10-06 Nicox S.A. Nitric oxide donating derivatives of latanoprost free acid
EP3088388A1 (en) 2015-04-30 2016-11-02 NicOx S.A. Nitric oxide donating derivatives of prostaglandins
JP7055802B2 (ja) 2016-11-08 2022-04-18 ボシュ・アンド・ロム・インコーポレイテッド 正常眼圧緑内障を処置するための一酸化窒素放出プロスタグランジン誘導体
KR102069205B1 (ko) * 2017-08-09 2020-01-22 연성정밀화학(주) 라타노프로스틴 부노드의 제조 방법 및 그를 위한 중간체

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3922293A (en) * 1971-12-30 1975-11-25 Upjohn Co Prostaglandin F-type 9-monoacylates
US4952581A (en) * 1987-04-03 1990-08-28 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
ES2213504T1 (es) * 1988-09-06 2004-09-01 Pfizer Health Ab Derivados de prostaglandina para el tratamiento del glaucoma o hipertension ocular.
CA2146127C (en) * 1992-10-13 2000-06-13 Louis Desantis, Jr. Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma
US5625083A (en) * 1995-06-02 1997-04-29 Bezuglov; Vladimir V. Dinitroglycerol esters of unsaturated fatty acids and prostaglandins
IT1295694B1 (it) * 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
IT1292377B1 (it) * 1997-06-19 1999-02-08 Nicox Sa Composizioni farmaceutiche a base di prostaglandine
US6417228B1 (en) * 1998-11-02 2002-07-09 Alcon Manufacturing, Ltd.. 13-Aza prostaglandins for the treatment of glaucoma and ocular hypertension
US7186744B2 (en) 2003-11-13 2007-03-06 Allergan, Inc. Prostamides for the treatment of glaucoma and related diseases
EP1704141B1 (en) * 2004-01-05 2016-02-24 Nicox S.A. Prostaglandin nitrooxyderivatives

Also Published As

Publication number Publication date
WO2007000641A8 (en) 2008-03-06
GT200600277A (es) 2007-02-14
WO2007000641A2 (en) 2007-01-04
PE20070120A1 (es) 2007-02-09
TW200730179A (en) 2007-08-16
US7718656B2 (en) 2010-05-18
WO2007000641A3 (en) 2007-03-22
NL1032046A1 (nl) 2007-01-02
JP2009501150A (ja) 2009-01-15
AR057414A1 (es) 2007-12-05
US20090062296A1 (en) 2009-03-05
EP1899295A2 (en) 2008-03-19
CA2613748A1 (en) 2007-01-04
NL1032046C2 (nl) 2007-04-24

Similar Documents

Publication Publication Date Title
CR20110131A (es) Derivados de prostaglandinas
UY29627A1 (es) Derivados de prostaglandina
UY29099A1 (es) Fenilaminotiazoles sustituidos y su uso
BRPI0912182A2 (pt) distribuição de liberação prolongada de agentes ativos pára tratar glaucoma e hipertensão ocular
DOP2013000212A (es) Formas cristalinas del dimetoxi-docetaxel y sus procedimientos de preparacion
UY30060A1 (es) Inhibición de la rho quinasa mediada por arni para el tratamiento de trastornos
PA8544901A1 (es) Derivados de oxazol
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma
ATE477805T1 (de) 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl- y-aminopropyl-azalide mit antimalaria-aktivität
EA200870396A1 (ru) Лечение аллергических заболеваний глаз
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
AR059928A1 (es) Metodos y dispositivos oftalmicos usados en el tratamiento de alergias oculares
CL2010001406A1 (es) Composicion farmaceutica oftalmica que comprende povidona yodada, y un compuesto antiinflamatorio esteroidal, un compuesto antiinflamatorio no esteroidal, un antibacteriano, un antialergico o un compuesto antiglaucoma; y metodo para preservar la composicion.
ECSP10010196A (es) Derivados de amidas del ácido 6,7-dihidro-5h-imidazo[1,2-a]imidazol-3-carboxílico
GT201400050A (es) Derivados de anilina, su preparación y su aplicación terapéutica
BR112012028437A2 (pt) solução oftálmica, e, método para tratar glaucoma ou hipertensão ocular
HN2010000128A (es) Imidazoles sustituidos con heterociclilamida
ES2969139T3 (es) Composiciones para el tratamiento del glaucoma e hipertensión ocular
UY33153A (es) Formulación tópica oftálmica de péptidos
ITMI20070890A1 (it) Composizioni oftalmiche per il trattamento della ipertensione oculare e del glaucoma
IT1398378B1 (it) Citicolina per il trattamento del glaucoma e dell'ipertensione oculare.
EA201300310A1 (ru) Применение агонистов аденозиновых а1-рецепторов для лечения глаукомы и внутриглазной гипертензии
AR088031A1 (es) Articulo absorbente
AR064015A1 (es) Inhibicion mediada por arni de acuaporina 1 para tratamiento de afecciones relacionadas con pio
GT201200017A (es) Preparacion de (r) y (s) - (3,4-difluoro-2-(2-fluoro-4-yodo-fenilamino-6-metoxifenil)-1-(2,3-dihidroxipropil) ciclopropan-1-sulfonamida y derivados protegidos de los mismos:

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160831